胃腺癌的分子发病机制和新靶点。
Molecular pathogenesis and emerging targets of gastric adenocarcinoma.
机构信息
Department of Cancer Cell Biology, West Virginia University Cancer Institute, West Virginia University, Morgantown, West Virginia, USA.
Department of Surgery, Department of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, West Virginia, USA.
出版信息
J Surg Oncol. 2022 Jun;125(7):1079-1095. doi: 10.1002/jso.26874.
Abstract
Gastric adenocarcinoma (GC) is a devastating disease and is the third leading cause of cancer deaths worldwide. This heterogeneous disease has several different classification systems that consider histological appearance and genomic alterations. Understanding the etiology of GC, including infection, hereditary conditions, and environmental factors, is of particular importance and is discussed in this review. To improve survival in GC, we also must improve our therapeutic strategies. Here, we discuss new targets that warrant further exploration.
摘要
胃腺癌（GC）是一种破坏性疾病，是全球癌症死亡的第三大主要原因。这种异质性疾病有几种不同的分类系统，考虑了组织学表现和基因组改变。了解 GC 的病因，包括感染、遗传条件和环境因素，尤为重要，本文对此进行了讨论。为了提高 GC 的生存率，我们还必须改进治疗策略。在这里，我们讨论了值得进一步探索的新靶点。
相似文献
1
Molecular pathogenesis and emerging targets of gastric adenocarcinoma.
J Surg Oncol. 2022 Jun;125(7):1079-1095. doi: 10.1002/jso.26874.
2
Updates on Management of Gastric Cancer.
Curr Oncol Rep. 2019 Jun 24;21(8):67. doi: 10.1007/s11912-019-0820-4.
3
Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma.
Gastroenterology. 2015 Oct;149(5):1153-1162.e3. doi: 10.1053/j.gastro.2015.05.059. Epub 2015 Jun 12.
4
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer.
Gut. 2013 Aug;62(8):1100-11. doi: 10.1136/gutjnl-2011-301373. Epub 2012 Jun 26.
5
A review of the genomics of gastric cancer.
Clin Gastroenterol Hepatol. 2006 Apr;4(4):416-25. doi: 10.1016/j.cgh.2006.01.019.
6
Genetics of Gastric Cancer.
Surg Clin North Am. 2017 Apr;97(2):345-370. doi: 10.1016/j.suc.2016.11.009.
7
Genomic pathobiology of gastric carcinoma.
Pathol Int. 2017 Feb;67(2):63-71. doi: 10.1111/pin.12493. Epub 2016 Dec 22.
8
New therapeutic options opened by the molecular classification of gastric cancer.
World J Gastroenterol. 2018 May 14;24(18):1942-1961. doi: 10.3748/wjg.v24.i18.1942.
9
Mapping the genomic diaspora of gastric cancer.
Nat Rev Cancer. 2022 Feb;22(2):71-84. doi: 10.1038/s41568-021-00412-7. Epub 2021 Oct 26.
10
Current treatment and recent progress in gastric cancer.
CA Cancer J Clin. 2021 May;71(3):264-279. doi: 10.3322/caac.21657. Epub 2021 Feb 16.
引用本文的文献
1
Trends and hot spots in research on the prognostic value of gastric cancer biomarkers in the context of the Lauren classification: a bibliometric analysis.
Front Med (Lausanne). 2025 Jul 22;12:1612256. doi: 10.3389/fmed.2025.1612256. eCollection 2025.
2
Immune regulation in gastric adenocarcinoma is linked with therapeutic efficacy and improved recovery.
Front Genet. 2023 Aug 11;14:1238248. doi: 10.3389/fgene.2023.1238248. eCollection 2023.
3
A CT-based radiomics signature for prediction of HER2 overexpression and treatment efficacy of trastuzumab in advanced gastric cancer.
Transl Cancer Res. 2022 Dec;11(12):4326-4337. doi: 10.21037/tcr-22-1690.
4
Identification of cuproptosis-associated IncRNAs signature and establishment of a novel nomogram for prognosis of stomach adenocarcinoma.
Front Genet. 2022 Sep 9;13:982888. doi: 10.3389/fgene.2022.982888. eCollection 2022.
5
Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers.
Cancers (Basel). 2022 Jul 20;14(14):3524. doi: 10.3390/cancers14143524.
6
KLF10 Functions as an Independent Prognosis Factor for Gastric Cancer.
Medicina (Kaunas). 2022 May 26;58(6):711. doi: 10.3390/medicina58060711.
本文引用的文献
1
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
Cancer. 2022 Mar 1;128(5):995-1003. doi: 10.1002/cncr.34019. Epub 2021 Dec 8.
2
Expression of Matrix Metalloproteinase-9 in Gastric Cancer.
Cureus. 2021 Sep 22;13(9):e18195. doi: 10.7759/cureus.18195. eCollection 2021 Sep.
3
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
Gastric Cancer. 2022 Jan;25(1):197-206. doi: 10.1007/s10120-021-01227-z. Epub 2021 Sep 1.
4
infection has a detrimental impact on the efficacy of cancer immunotherapies.
Gut. 2022 Mar;71(3):457-466. doi: 10.1136/gutjnl-2020-323392. Epub 2021 Jul 12.
5
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
6
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Ann Oncol. 2021 May;32(5):609-619. doi: 10.1016/j.annonc.2021.02.005. Epub 2021 Feb 19.
7
Current treatment and recent progress in gastric cancer.
CA Cancer J Clin. 2021 May;71(3):264-279. doi: 10.3322/caac.21657. Epub 2021 Feb 16.
8
Downregulation of E-cadherin in pluripotent stem cells triggers partial EMT.
Sci Rep. 2021 Jan 21;11(1):2048. doi: 10.1038/s41598-021-81735-1.
9
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Future Oncol. 2021 Apr;17(10):1155-1164. doi: 10.2217/fon-2020-1007. Epub 2020 Dec 2.
10
Clinical Characteristics and Prognosis of Gastric Cancer Patients with Germline Mutations: Report of Ten Cases and a Literature Review.
Onco Targets Ther. 2020 Nov 13;13:11637-11644. doi: 10.2147/OTT.S276814. eCollection 2020.
Zotero 插件